NASDAQ:CGEM Cullinan Therapeutics (CGEM) Stock Price, News & Analysis $7.86 -0.88 (-10.07%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$8.29 +0.43 (+5.46%) As of 05:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cullinan Therapeutics Stock (NASDAQ:CGEM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cullinan Therapeutics alerts:Sign Up Key Stats Today's Range$7.59▼$8.6650-Day Range$5.75▼$8.7452-Week Range$5.68▼$17.79Volume1.53 million shsAverage Volume1.40 million shsMarket Capitalization$464.29 millionP/E RatioN/ADividend YieldN/APrice Target$26.00Consensus RatingModerate Buy Company Overview Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Read More Cullinan Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreCGEM MarketRank™: Cullinan Therapeutics scored higher than 68% of companies evaluated by MarketBeat, and ranked 284th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingCullinan Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCullinan Therapeutics has a consensus price target of $26.00, representing about 230.8% upside from its current price of $7.86.Amount of Analyst CoverageCullinan Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cullinan Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Cullinan Therapeutics are expected to decrease in the coming year, from ($3.04) to ($3.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cullinan Therapeutics is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cullinan Therapeutics is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCullinan Therapeutics has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Cullinan Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.81% of the float of Cullinan Therapeutics has been sold short.Short Interest Ratio / Days to CoverCullinan Therapeutics has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Cullinan Therapeutics has recently decreased by 1.29%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCullinan Therapeutics does not currently pay a dividend.Dividend GrowthCullinan Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted16.81% of the float of Cullinan Therapeutics has been sold short.Short Interest Ratio / Days to CoverCullinan Therapeutics has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Cullinan Therapeutics has recently decreased by 1.29%, indicating that investor sentiment is improving. News and Social Media3.1 / 5News Sentiment0.50 News SentimentCullinan Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Cullinan Therapeutics this week, compared to 4 articles on an average week.Search Interest8 people have searched for CGEM on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.MarketBeat Follows3 people have added Cullinan Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Cullinan Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,829,099.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 6.07% of the stock of Cullinan Therapeutics is held by insiders.Percentage Held by Institutions86.31% of the stock of Cullinan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cullinan Therapeutics' insider trading history. Receive CGEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cullinan Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CGEM Stock News HeadlinesCullinan Therapeutics (NASDAQ:CGEM) Major Shareholder Acquires $2,040,913.28 in StockOctober 11, 2025 | insidertrades.comCullinan Therapeutics: Worthy Of A Small PositionOctober 17 at 7:01 AM | seekingalpha.comThe 7 Warning Signals Flashing Red Right NowA free report revealing the 7 key indicators that have predicted every major economic collapse since 1929. Right now, all seven are flashing red simultaneously for the first time since 2007. These aren't the signals you'll see on CNBC. | American Alternative (Ad)Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Rating of "Moderate Buy" by AnalystsOctober 17 at 2:38 AM | americanbankingnews.comCullinan Management (CGEM) Gets a Buy from Clear StreetOctober 15, 2025 | theglobeandmail.comTaiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025October 12, 2025 | prnewswire.comLynx1 capital buys Cullinan Therapeutics (CGEM) shares worth $9.8mOctober 10, 2025 | investing.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Novan (NOVN) and Cullinan Management (CGEM)September 26, 2025 | theglobeandmail.comSee More Headlines CGEM Stock Analysis - Frequently Asked Questions How have CGEM shares performed this year? Cullinan Therapeutics' stock was trading at $12.18 on January 1st, 2025. Since then, CGEM stock has decreased by 35.5% and is now trading at $7.86. How were Cullinan Therapeutics' earnings last quarter? Cullinan Therapeutics, Inc. (NASDAQ:CGEM) released its earnings results on Thursday, August, 7th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by $0.24. When did Cullinan Therapeutics IPO? Cullinan Therapeutics (CGEM) raised $149 million in an initial public offering on Friday, January 8th 2021. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager. Who are Cullinan Therapeutics' major shareholders? Cullinan Therapeutics' top institutional shareholders include Assenagon Asset Management S.A. (0.30%). Insiders that own company stock include Lynx1 Capital Management Lp, Nadim Ahmed, Jeffrey Alan Jones, Corrine Savill, Jennifer Michaelson and Jeffrey Trigilio. View institutional ownership trends. How do I buy shares of Cullinan Therapeutics? Shares of CGEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cullinan Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cullinan Therapeutics investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Visa (V). Company Calendar Last Earnings8/07/2025Today10/19/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CGEM CIK1789972 Webwww.cullinanoncology.com Phone617-410-4650FaxN/AEmployees30Year Founded2016Price Target and Rating Average Price Target for Cullinan Therapeutics$26.00 High Price Target$32.00 Low Price Target$22.00 Potential Upside/Downside+230.8%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($3.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$167.38 million Net MarginsN/A Pretax MarginN/A Return on Equity-36.56% Return on Assets-34.82% Debt Debt-to-Equity RatioN/A Current Ratio9.83 Quick Ratio9.83 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.14 per share Price / Book0.78Miscellaneous Outstanding Shares59,070,000Free Float55,488,000Market Cap$464.29 million OptionableOptionable Beta-0.12 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:CGEM) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredThis Crypto Is Set to Explode in JanuaryCurious about crypto but still stuck scrolling endless threads? People who get in early aren’t just lucky—they...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCould this strange machine change society forever?A mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.